ABSTRACT
The precision of precision medicine is challenged by the difficulty in generating functional proteomics data when compared with the more robust genomics and transcriptomics. In the absence of a comprehensive molecular model of the pathological human world, we can not predict responses and sensitivities from genes and transcript variations; hence, it is argued we need additional information in the form of functional proteomics. This is defined not as simple concentrations of proteins (itself not an easy data set), but rather the state of proteins. Whether a key protein is, for example, active, modified, in a complex, or on a membrane is typically crucial to understanding a pathological state. These features are hard to determine robustly in patient samples, but the use of dual detection methods provide avenues into these problems. Alongside more general proteomics methods, commentary is given regarding some of the emerging technologies in this area.
